Skip to content

Latest News

USFDA accepts Dr Reddy#39;s Biologics License Application for review; stock dips

USFDA accepts Dr Reddy#39;s Biologics License Application for review; stock dips

Dr. Reddy’s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets. Read More ​ Dr. Reddy’s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets. Dr. Reddy’s rituximab biosimilar… Read More »USFDA accepts Dr Reddy#39;s Biologics License Application for review; stock dips

en_USEnglish